Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

Schumacher, H. RALPH, Becker, Michael A., Wortmann, Robert L., MacDonald, Patricia A., Hunt, Barbara, Streit, Janet, Lademacher, Christopher, Joseph‐Ridge, Nancy·2008·Arthritis Care & Research

DOI 10.1002/art.24209

Cited by (641)

Items 101–200 of 641

Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment
Thomas Bardin, Gérard Chalès, Tristan Pascart, René-Marc Flipo, Hang‐Korng Ea, Jean‐Claude Roujeau, Aurélie Delayen, Pierre Clerson · 2015 · Joint Bone Spine
Update on gout and hyperuricemia
Joshua F. Baker, H. Ralph Schumacher · 2009 · International Journal of Clinical Practice
Prophylaxis for acute gout flares after initiation of urate-lowering therapy
Augustin Latourte, Thomas Bardin, Pascal Richette · 2014 · Lara D. Veeken
Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study
Tristan Pascart, Agathe Grandjean, Benoist Capon, Julie Legrand, Nasser Namane, Vincent Ducoulombier, Marguerite Motte, Marie Vandecandelaere, Hélène Luraschi, Catherine Godart et al. · 2018 · Arthritis Research & Therapy
Uric acid in CKD: has the jury come to the verdict?
Barbara Bonino, Giovanna Leoncini, Elisa Russo, Roberto Pontremoli, Francesca Chiara Viazzi · 2020 · Journal of Nephrology
Pegloticase treatment of chronic refractory gout: Update on efficacy and safety
Naomi Schlesinger, Peter E. Lipsky · 2020 · Seminars in Arthritis and Rheumatism
Assessment of Tophus Size
Nicola Dalbeth, Opetaia Aati, Angela Gao, Meaghan E House, Qiliang Liu, Anne M. Horne, Anthony Doyle, Fiona Marion McQueen · 2011 · JCR Journal of Clinical Rheumatology
Allopurinol, uric acid, and oxidative stress in cardiorenal disease
Markus Riegersperger, Adrian Constantin Covic, David J.A. Goldsmith · 2011 · International Urology and Nephrology
New and improved strategies for the treatment of gout
Gerald F. Falasca, Natalie Dubchak · 2010 · International Journal of Nephrology and Renovascular Disease
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
Jasvinder A. Singh, Kasem S. Akhras, Aki Shiozawa · 2015 · Arthritis Research & Therapy
Preservation of Renal Function during Gout Treatment with Febuxostat: A Quantitative Study
Andrew Whelton, Patricia A. MacDonald, Solomon Chefo, Lhanoo Gunawardhana · 2013 · Postgraduate Medicine
Febuxostat for treating chronic gout
Jean H. Tayar, Maria Angeles Lopez-Olivo, Maria Eugenia Suarez-Almazor · 2012 · Cochrane Database of Systematic Reviews
Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative
Scott W. Graf, Samuel Whittle, Mihir D. Wechalekar, John HY Moi, Claire Barrett, Catherine Louise Hill, Geoff Littlejohn, Nora Lynch, Gabor A. C. Major, Andrew L. Taylor et al. · 2015 · International Journal of Rheumatic Diseases
CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
William B. White, Saima Chohan, Aruna Dabholkar, Barbara Hunt, Robert Jackson · 2012 · American Heart Journal
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function
Marilisa Bove, Arrigo F.G. Cicero, Claudio Borghi · 2017 · Current Hypertension Reports
Challenges Associated with the Management of Gouty Arthritis in Patients with Chronic Kidney Disease: A Systematic Review
Rodolfo Curiel, Nicolas Jose Guzman · 2012 · Seminars in Arthritis and Rheumatism
Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
Catrin Plumpton, Ana Alfirevic, Munir Pirmohamed, Dyfrig Arwyn Hughes · 2017 · Lara D. Veeken
Current and future therapies for gout
Tristan Pascart, Pascal Richette · 2017 · Expert Opinion on Pharmacotherapy
Difficult-to-Treat Gouty Arthritis
Naomi Schlesinger · 2011 · Drugs
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
Linggen Gao, Bin Wang, Ying H. Pan, Yan Lü, Rui Cheng · 2021 · Clinical Cardiology
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
Lisa K. Stamp, Anne M. Horne, Borislav Mihov, Jill M. Drake, Janine Haslett, Peter T. Chapman, CHRISTOPHER M. A. FRAMPTON, Nicola Dalbeth · 2023 · Annals of the Rheumatic Diseases
Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis
Peng Ye, Shumin Yang, Wenlong Zhang, Qiong Lv, Qingfeng Cheng, Mei Mei, Ting Luo, Lulu Liu, Shu‐Mei Chen, Qifu Li · 2013 · Clinical Therapeutics
Update on emerging urate-lowering therapies
Saima Chohan, Michael A. Becker · 2009 · Current Opinion in Rheumatology
Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study
Austin G. Stack, Michelle Elizabeth Johnson, Betina T. Blak, Alyssa Klein, Lewis Carpenter, Robert Morlock, Andrew Maguire, Victoria Parsons · 2019 · BMJ Open
2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout
Jose Paulo Lorenzo, Ma. Hanna Monica Z. Sollano, Evelyn O. Salido, Julie Li‐Yu, Sandra A. Tankeh‐Torres, Ida Ayu Ratih Wulansari Manuaba, Md Mujibur Rahman, Binoy J. Paul, Mo Yin Mok, Monika De Silva et al. · 2021 · International Journal of Rheumatic Diseases
Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout
Eric Jutkowitz, Hyon K. Choi, Laura T. Pizzi, Karen M. Kuntz · 2014 · Annals of Internal Medicine
The Challenges of Gout Management in the Elderly
Lisa K. Stamp, Sarah Jordan · 2011 · Drugs & Aging
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia
Shaoyong Xu, Xiangyang Liu, Jie Ming, Shenren Chen, Yangang Wang, Xiumei Liu, Hong Liu, Yongde Peng, Jianqin Wang, Jinying Lin et al. · 2015 · International Journal of Rheumatic Diseases
International position paper on febuxostat
Tim Jansen, Pascal Richette, Fernando Pérez-Ruiz, Anne‐Kathrin Tausche, Philip-André Guerne, Leonardo Punzi, Burkhard F. Leeb, В Г Барскова, Till Uhlig, José Bravo Pimentão et al. · 2010 · Clinical Rheumatology
Management of hyperuricemia in gout: focus on febuxostat
Mark Reinders, Tim Jansen · 2010 · Clinical Interventions in Aging
Synthesis and xanthine oxidase inhibitory activity of 5,6-dihydropyrazolo/pyrazolo[1,5-c]quinazoline derivatives
Deependra Kumar, Gagandeep Kaur, Arvind Negi, Sanjeev Kumar, Sandeep Singh, Raj Kumar · 2014 · Bioorganic Chemistry
An update on the pathology and clinical management of gouty arthritis
Emilio B. González · 2011 · Clinical Rheumatology
Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat
Bishoy Kamel, Garry G. Graham, Kenneth M. Williams, Kevin D. Pile, Richard Osborne Day · 2016 · Clinical Pharmacokinetics
Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD)
Lieke E.J.M. Scheepers, Andrea Michelle Burden, Ilja C.W. Arts, Bart Spaetgens, Patrick Cyriel Souverein, Frank de Vries, Annelies E. R. C. H. Boonen · 2018 · Lara D. Veeken
Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis
Chi‐Hua Chen, Chun‐Bing Chen, Chee‐Jen Chang, Yu Jr Lin, Chuang‐Wei Wang, Ching‐Chi Chi, Chun‐Wei Lu, Wei‐Ti Chen, Ren‐You Pan, Shih‐Chi Su et al. · 2019 · Clinical Pharmacology & Therapeutics
Hyperuricemia and Gout: New Concepts in Diagnosis and Management
Paul P. Doghramji, Robert L. Wortmann · 2012 · Postgraduate Medicine
Hyperuricaemia and gout: state of the art and future perspectives
Nicola Dalbeth, Alexander K.-L. So · 2010 · Annals of the Rheumatic Diseases
Cost–Effectiveness Analysis of Genotyping for HLA-B*5801 and an Enhanced Safety Program in Gout Patients Starting Allopurinol in Singapore
Di Dong, Wei Chuen Tan‐Koi, Gim Gee Teng, Eric Andrew Finkelstein, Cynthia Sung · 2015 · Pharmacogenomics
Up-titration of allopurinol in patients with gout
Claudine G. Jennings, Isla S. Mackenzie, Rob Flynn, Ian Ford, George Nuki, Raffaele De Caterina, Philip L. Riches, Stuart H. Ralston, Thomas MacLennan MacDonald · 2014 · Seminars in Arthritis and Rheumatism
Gout‐Related Health Care Utilization in US Emergency Departments, 2006 Through 2008
Rohini Garg, Harlan R Sayles, Fang Yu, Kaleb D. Michaud, Jasvinder A. Singh, Kenneth G. Saag, Ted R. Mikuls · 2013 · Arthritis Care & Research
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia – A systematic review and meta-analysis
Cheng‐Wei Liu, Wei-Cheng Chang, Chiao‐Chin Lee, Wen‐Yi Shau, Fu-Shun Hsu, Man‐Ling Wang, Tsung‐Chih Chen, Chiao Lo, Juey‐Jen Hwang · 2019 · Nutrition Metabolism and Cardiovascular Diseases
Cost-effectiveness of febuxostat in chronic gout
Stephen M. Beard, Birgitta G. von Scheele, George Nuki, Isobel V. Pearson · 2013 · The European Journal of Health Economics
Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study
Ching-Yen Su, Li‐Jiuan Shen, Song‐Chou Hsieh, Lian‐Yu Lin, Fang‐Ju Lin · 2019 · Mayo Clinic Proceedings
Effect of lemon water soluble extract on hyperuricemia in a mouse model
Lin Chen, Ming Li, Jinlong Wu, Jinxue Li, Zhaocheng Ma · 2019 · Food & Function
Renal stones
Adie Viljoen, Rabia Chaudhry, John A Bycroft · 2018 · Annals of Clinical Biochemistry International Journal of Laboratory Medicine
Serum Urate as a Soluble Biomarker in Chronic Gout—Evidence that Serum Urate Fulfills the OMERACT Validation Criteria for Soluble Biomarkers
Lisa K. Stamp, Xiaoyu Zhu, Nicola Dalbeth, Sarah Jordan, N. Lawrence Edwards, William John Taylor · 2010 · Seminars in Arthritis and Rheumatism
Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study
Yuki Tsuruta, Kan Kikuchi, Yukio Tsuruta, Yuko Sasaki, Takahito Moriyama, Mitsuyo Itabashi, Takashi Takei, Keiko Uchida, Takashi Akiba, Ken Tsuchiya et al. · 2015 · Hemodialysis International
Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers
Pierre‐Antoine Juge, Marie‐Elise Truchetet, Évangéline Pillebout, Sébastien Ottaviani, Cecile M. Vigneau, Clotilde Loustau, Divi Cornec, Tristan Pascart, Renaud Snanoudj, F. Bailly et al. · 2016 · Joint Bone Spine
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Brian F. Mandell, Anthony E. T. Yeo, Peter E. Lipsky · 2018 · Arthritis Research & Therapy
Gout: Current Insights and Future Perspectives
Howard S. Smith, Donna Bracken, Joshua M. Smith · 2011 · Journal of Pain
Febuxostat for treatment of chronic gout
Charnelda L. Gray, Nafesa Walters-Smith · 2011 · American Journal of Health-System Pharmacy
Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)
Uta Kiltz, Rieke Alten, Martin Fleck, K. Krüger, Bernhard Manger, Ulf Müller‐Ladner, Hubert G Nüßlein, Monika A Reuss-Borst, Andreas Schwarting, Hendrik Schulze‐Koops et al. · 2016 · Zeitschrift für Rheumatologie
Febuxostat
Eliseo Pascual, Francisca Sivera, Uma Yasothan, Peter N. Kirkpatrick · 2009 · Nature Reviews Drug Discovery
Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors
David S. Goldfarb, PATRICIA A. MacDONALD, Barbara Hunt, Lhanoo Gunawardhana · 2011 · The Journal of Rheumatology
Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis
Li Zhao, Ling Cao, Tianyi Zhao, Xue Yang, Xiaoxia Zhu, Hejian Zou, Weiguo Wan, Yu Xue · 2020 · Chinese Medical Journal
Advances in pharmacotherapy for the treatment of gout
Philip Cameron Robinson, Nicola Dalbeth · 2014 · Expert Opinion on Pharmacotherapy
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study
K-H Yu, J-H Lai, P-N Hsu, Chen Dy, C-J Chen, H-Y Lin · 2016 · Scandinavian Journal of Rheumatology
Cost-effectiveness analysis of HLA-B*58
Huey Yi Chong, Yi Heng Lim, Juthamas Prawjaeng, Wichittra Tassaneeyakul, Zahurin Mohamed, Nathorn Chaiyakunapruk · 2017 · Pharmacogenetics and Genomics
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease
Yukinao Sakai, Tomoyuki Otsuka, Dai Ohno, Tsuneo Murasawa, Naoki Sato, Shuichi Tsuruoka · 2013 · Renal Failure
Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis
Isabel Castrejón, Esther Toledano, María Piedad Rosario, Estíbaliz Loza, Fernando Pérez-Ruiz, Loreto Carmona · 2014 · Rheumatology International
Xanthine oxidoreductase and its inhibitors: relevance for gout
Richard Osborne Day, Bishoy Kamel, Diluk R. W. Kannangara, Kenneth M. Williams, Garry G. Graham · 2016 · Clinical Science
Development of dual drug loaded solid self microemulsifying drug delivery system: Exploring interfacial interactions using QbD coupled risk based approach
Aamin M. Vohra, Chintankumar V. Patel, Praveen Kumar, Hetal Paresh Thakkar · 2017 · Journal of Molecular Liquids
The role of febuxostat in gout
Thomas Bardin, Pascal Richette · 2018 · Current Opinion in Rheumatology
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
Amayelle Rey, Benjamin Batteux, Solène M. Laville, Justine Marienne, Kamel Masmoudi, Valérie Gras‐Champel, Sophie Liabeuf · 2019 · Arthritis Research & Therapy
2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout
Lorenzo, J.P.P., Sollano, M.H.M.Z., Salido, E.O., Li‐Yu, J., Tankeh‐Torres, S.A., Wulansari Manuaba, I.A.R., Rahman, M.M., Paul, B.J., Mok, M.Y., de Silva, M. et al. · 2022 · Murdoch University Research Portal
Febuxostat: drug review and update
Harmanjot Kaur Grewal, Joseph R Martinez, Luis R. Espinoza · 2014 · Expert Opinion on Drug Metabolism & Toxicology
Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
John A. Cuenca, Javier Balda, Ana Palacio, Larry Young, Michael H. Pillinger, Leonardo J. Tamariz · 2019 · International Journal of Rheumatology
Progress in the pharmacotherapy of gout
John S. Sundy · 2010 · Current Opinion in Rheumatology
Treatment of Chronic Gouty Arthritis: It Is Not Just About Urate-Lowering Therapy
Naomi Schlesinger · 2012 · Seminars in Arthritis and Rheumatism
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
Austin G. Stack, David Han, Ronald Goldwater, Susanne A. Johansson, Nalina Dronamraju, Jan Oscarsson, EVA K. JOHNSSON, JOANNA R. PARKINSON, Fredrik Erlandsson · 2020 · The Journal of Clinical Endocrinology & Metabolism
Gout: optimizing treatment to achieve a disease cure
José Antonio Bernal, Neus Quilis, Mariano Andrés, Francisca Sivera, Eliseo Pascual · 2016 · Therapeutic Advances in Chronic Disease
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study
On behalf of the PRIZE Study Investigators, Jun‐ichi Oyama, Atsushi Tanaka, Yasunori Sato, Hirofumi Tomiyama, Masataka Sata, Tomoko Ishizu, Isao Taguchi, Takanori Kuroyanagi, Hiroki Teragawa et al. · 2016 · Cardiovascular Diabetology
Treat to target in gout
Fernando Pérez-Ruiz, Aitana Moreno-Lledó, Irati Urionagüena, Alastair J Dickson · 2017 · Lara D. Veeken
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes
Subuhi Kaul, Manasvi Gupta, Dhrubajyoti Bandyopadhyay, Adrija Hajra, PRAKASH C. DEEDWANIA, Edward Roddy, Mamas A. Mamas, Allan L. Klein, Carl J. Lavie, Gregg C. Fonarow et al. · 2020 · American Journal of Cardiovascular Drugs
Purification, identification, and computational analysis of xanthine oxidase inhibitory peptides from kidney bean
Yuqun Wu, Hui He, Tao Hou · 2021 · Journal of Food Science
Medical therapy for calculus disease
Shrawan Kumar Singh, Mayank Mohan Agarwal, Sumit Kumar Sharma · 2011 · British Journal of Urology
Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model
Jianbiao Peng, Qiyue Hu, Chunyan Gu, Bonian Liu, Fangfang Jin, Jijun Yuan, Jun Feng, Lei Justan Zhang, Jiong Lan, Qing Dong et al. · 2015 · Bioorganic & Medicinal Chemistry Letters
Efficacy and safety of febuxostat in patients with hyperuricemia and gout
Ignacio García-Valladares, Tahir Angez Khan, Luis R. Espinoza · 2011 · Therapeutic Advances in Musculoskeletal Disease
Italian Society of Rheumatology recommendations for the management of gout
MARIA MANARA, Alessandra Bortoluzzi, Marta Favero, Immacolata Prevete, Carlo Alberto Scirè, Gerolamo Bianchi, Claudio Borghi, Marco A Cimmino, G. M. D'Avola, Giovambattista Desideri et al. · 2013 · Reumatismo
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra S. Steinberg, Bradley D. Vince, Yun‐Jung Choi, Robert L. Martin, Charles A. McWherter, Pol F. Boudes · 2016 · The Journal of Rheumatology
Benzoflavone derivatives as potent antihyperuricemic agents
Jatinder Vir Singh, Gurbachan Mal, Gurleen Kaur, Manish Gupta, Amritpal Singh, Kunal Nepali, Harbinder Singh, Sahil Sharma, Preet Mohinder Singh Bedi · 2018 · MedChemComm
Management of Gout in the Older Adult
Fravel, Michelle A., Ernst, Michael E. · 2011 · The American Journal of Geriatric Pharmacotherapy
Naturally Occurring Compounds: New Potential Weapons against Oxidative Stress in Chronic Kidney Disease
Lorenzo Federico Signorini, Simona Granata, Antonio Lupo, Gianluigi Zaza · 2017 · International Journal of Molecular Sciences
Gender and Ethnic Inequities in Gout Burden and Management
Andrea García-Guillén, Leanne Te Karu, Jasvinder A. Singh, Nicola Dalbeth · 2020 · Rheumatic Disease Clinics of North America
UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis
Esther Ebstein, Marine Forien, Eleonora Norkuvienė, Pascal Richette, Gaël Mouterde, C. Daïen, Hang‐Korng Ea, Claire Brière, Frédéric Lioté, Mykolas Petraitis et al. · 2020 · Joint Bone Spine
Therapeutic strategies in inflammasome mediated diseases of the liver
Rafaz Hoque, Yoram Vodovotz B, Wajahat Zafar Mehal · 2012 · Journal of Hepatology
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist
Marwan Hmoud Adwan · 2017 · Current Rheumatology Reports
Febuxostat for the treatment of hyperuricaemia in gout
Philip Cameron Robinson, Nicola Dalbeth · 2018 · Expert Opinion on Pharmacotherapy
Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares
Rose Soskind, Daniel T. Abazia, Mary Barna Bridgeman · 2017 · Expert Opinion on Pharmacotherapy
Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean
Joong Kyong Ahn · 2023 · Journal of Rheumatic Diseases
Febuxostat for the chronic management of hyperuricemia in patients with gout
Sandra Pamela Chinchilla, Irati Urionagüena, Fernando Pérez-Ruiz · 2016 · Expert Review of Clinical Pharmacology
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo‐Controlled Study
Kenneth G. Saag, Michael A. Becker, Andrew Whelton, Barbara Hunt, Majin Castillo, Krisztina Kisfalvi, Lhanoo Gunawardhana · 2018 · Arthritis & Rheumatology
The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3–5
Xuemei Liu, Huifang Wang, Ruixia Ma, Leping Shao, Wei Zhang, Wei Jiang, Congjuan Luo, Tingting Zhai, Yan Xu · 2018 · Clinical and Experimental Nephrology
Development of a prediction model for inpatient gout flares in people with comorbid gout
Kanon Jatuworapruk, Rebecca Grainger, Nicola Dalbeth, William John Taylor · 2019 · Annals of the Rheumatic Diseases
Management of Gout in Older Adults
Karl T Hoskison, Robert L. Wortmann · 2007 · Drugs & Aging
Gout and Cardiovascular Disease: Mechanisms, Risk Estimations, and the Impact of Therapies
Mariano Andrés · 2023 · Gout Urate and Crystal Deposition Disease
Women with gout: Efficacy and safety of urate‐lowering with febuxostat and allopurinol
Saima Chohan, Michael A. Becker, Patricia A. MacDonald, Solomon Chefo, Robert L. Jackson · 2011 · Arthritis Care & Research
Dietary supplements and medicinal plants in urolithiasis: diet, prevention, and cure
Mitul Oswal, Ryan Varghese, Tanmay Zagade, Chetan Dhatrak, Rohit Sharma, Dileep Kumar · 2023 · Journal of Pharmacy and Pharmacology
Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia
Akihiro Nakagomi, Yoshiyuki Saiki, Satsuki Noma, Keiichi Kohashi, Taichirou Morisawa, Munenori Kosugi, Yoshiki Kusama, Hirotsugu Atarashi, Wataru Shimizu · 2015 · IJC Metabolic & Endocrine
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
Lhanoo Gunawardhana, Michael A. Becker, Andrew Whelton, Barbara Hunt, Majin Castillo, Kenneth G. Saag · 2018 · Arthritis Research & Therapy